ReviewNPJ Parkinson's disease2023
Gastrointestinal disorders in Parkinson's disease and other Lewy body diseases.
Review in NPJ Parkinson's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Bibliometric analysis of global research trends on regulatory T cells in neurological diseases.Frontiers in neurology · 2023Pooled it
- A qPCR-based approach targeting the microbial gene markerJournal of Parkinson's disease · 2026Article
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- Systemic Endotoxemia, Inflammatory Activation, and Lipid Dysregulation in Parkinson's Disease: Evidence from Circulating LPS-Related Biomarkers and Plasma Lipids.International journal of molecular sciences · 2026Article
- Identifying candidate gut microbiota indicators for Alzheimer's disease through integrated data.mSystems · 2026Article
- The Microbiome-Neurodegeneration Interface: Mechanisms, Evidence, and Future Directions.Cells · 2026Review
- Distinct gut and oral microbial profiles differentiate patients with symmetric/asymmetric Parkinson's disease.Frontiers in human neuroscience · 2026Article
- Article
- Dysbiosis and the gut-brain axis impairment in the pathophysiology of Alzheimer's disease and related dementias: is 'pathobiome' an etiological element?Essays in biochemistry · 2025Review
- A Narrative Review on the Role of Microbiota and Microglia in Premotor Symptoms of Parkinson's Disease.Neurotoxicity research · 2025Review
- Akkermansia muciniphila: a microbial guardian against oxidative stress-gut microbiota crosstalk and clinical prospects.Journal of translational medicine · 2025Review
- Pareidolia and Constipation in De Novo Parkinson's Disease: Symptomatic Markers of a Shared Clinical Pattern.Cureus · 2025Article
- Strain-specific effects of Desulfovibrio on neurodegeneration and oxidative stress in a Caenorhabditis elegans PD model.NPJ Parkinson's disease · 2025Article
- Blood microbiome signatures in the REM sleep behavior disorder-Lewy body disease continuum.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Fasting and postprandial Ghrelin levels in Parkinson's disease: a systematic review and meta-analysis.NPJ Parkinson's disease · 2025Article
- Best Practice to Prevent Constipation in People Living With Dementia: A Scoping Review.International journal of older people nursing · 2025Article
- Elevated phenylacetylglutamine caused by gut dysbiosis associated with type 2 diabetes increases neutrophil extracellular traps formation and exacerbates brain infarction.Clinical science (London, England : 1979) · 2025Article
- The Gut-Brain Axis Based on α-Synuclein Propagation-Clinical, Neuropathological, and Experimental Evidence.International journal of molecular sciences · 2025Review
- Microbial metabolite 3-indolepropionic acid alleviated PD pathologies by decreasing enteric glia cell gliosisActa pharmaceutica Sinica. B · 2025Article
- Probiotics as Potential Treatments for Neurodegenerative Diseases: a Review of the Evidence fromBiomolecules & therapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease (PD) is pathologically characterized by the abnormal accumulation of α-synuclein fibrils (Lewy bodies) in the substantia nigra and other brain regions, although the role of Lewy bodies remains elusive. Constipation usually precedes the motor symptoms in PD, which is in accordance with the notion that α-synuclein fibrils start from the intestinal neural plexus and ascend to the brain in at least half of PD patients. The gut microbiota is likely to be involved in intestinal and brain pathologies. Analyses of the gut microbiota in PD, rapid-eye-movement sleep behavior disorder, and dementia with Lewy bodies suggest three pathological pathways. First, Akkermansia, which is increased in PD, degrades the intestinal mucus layer and increases intestinal permeability, which triggers inflammation and oxidative stress in the intestinal neural plexus. Second, decreased short-chain fatty acids (SCFAs)-producing bacteria in PD reduce the number of regulatory T cells. Third, SCFAs also aggravate microglial activation with an unelucidated pathway. In addition, in dementia with Lewy bodies (DLB), which is another form of α-synucleinopathies, increased genera, Ruminococcus torques and Collinsella, may mitigate neuroinflammation in the substantia nigra by increasing secondary bile acids. Interventions for the gut microbiota and their metabolites may potentially delay or mitigate the development and progression of PD and other Lewy body diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.